Since August, when the Food and Drug Administration (FDA) approved a minimally invasive heart valve procedure for an expanded group of patients with aortic stenosis, Raj Makkar, MD, vice president of Cardiovascular Innovation and Intervention at Cedars-Sinai, says many more patients are opting for the procedure known as transcatheter aortic valve replacement (TAVR).
With this latest approval, the procedure can now be performed on a wide spectrum of patients, from patients too sick to undergo open-heart surgery to those who would be considered low risk for open-heart surgery.
“The TAVR procedure allows us to replace a patient’s aortic valve without undergoing open-heart surgery,” said Makkar, the Stephen R. Corday, MD, Chair in Interventional Cardiology at Cedars-Sinai. “Now that low-risk patients can have TAVR, we are adding years to the lives of more and more people—and we are adding life to those years.”
Each year, more than 200,000 Americans are diagnosed with aortic valve stenosis—a stiffness of the heart valve’s leaflets that reduces the ability to fully open and close and causes the heart’s aortic valve to narrow and the heart muscle to become thicker and sometimes weaker.
To treat the condition, cardiac surgeons and interventionalists like Makkar use TAVR, a minimally invasive procedure during which an interventional cardiologist repairs the valve by using a catheter to insert a new valve into the aorta. Makkar’s team has performed TAVR on close to 3,500 patients, and he has taught his technique to interventionalists around the world.\